Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PBLA | US
0.02
5.14%
Healthcare
Biotechnology
30/06/2024
21/10/2024
0.34
0.33
0.34
0.32
Panbela Therapeutics Inc. a clinical-stage biopharmaceutical company together with its subsidiaries develops disruptive therapeutics for the treatment of patients with cancer. The company's lead product candidates are Ivospemin (SBP-101) which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM a combination of eflornithine (CPP-1X) and sulindac; and Eflornithine an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin (SBP-101). The company was formerly known as Sun BioPharma Inc. and changed its name to Panbela Therapeutics Inc. in December 2020. Panbela Therapeutics Inc. was incorporated in 2011 and is based in Waconia Minnesota.
View LessLow Debt to Equity (< 0.25)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
154.4%1 month
151.5%3 months
148.4%6 months
133.8%0.00
-
3.22
-0.40
0.45
-0.22
-
-
-
1.76M
1.76M
-
-
-
-
-798.16
0.07
3.07
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.12
Range1M
0.12
Range3M
0.14
Rel. volume
0.29
Price X volume
1.01K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Sorrento Therapeutics Inc | SRNE | Biotechnology | 0.003 | 1.90M | 11.11% | n/a | -101.21% |
Kiromic BioPharma Inc | KRBP | Biotechnology | 1.1 | 1.70M | -8.33% | n/a | -258.59% |
Innovation Pharmaceuticals Inc | IPIX | Biotechnology | 0.003 | 1.56M | 200.00% | n/a | 20.48% |
CohBar Inc | CWBR | Biotechnology | 0.5 | 1.45M | 0.00% | n/a | 0.00% |
Arch Therapeutics Inc | ARTH | Biotechnology | 0.3002 | 1.33M | 0.00% | n/a | 0.00% |
TC BioPharm (Holdings) plc American Depositary Shares | TCBP | Biotechnology | 2.27 | 1.30M | -55.14% | n/a | 131.42% |
Evofem Biosciences Inc | EVFM | Biotechnology | 0.0092 | 923.03K | -8.00% | 0.00 | 0.00% |
Seelos Therapeutics Inc | SEEL | Biotechnology | 1.13 | 832.04K | 11.88% | 0.00 | -36.10% |
International Stem Cell Corporation | ISCO | Biotechnology | 0.06 | 480.26K | 0.00% | n/a | 0.00% |
NexImmune Inc. Common Stock | NEXI | Biotechnology | 0.2514 | 350.62K | -23.82% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.22 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | 0.00 | 41.03 | Cheaper |
Price to Book | 3.22 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 148.41 | 72.80 | Riskier |
Debt to Equity | -0.40 | -1.23 | Expensive |
Debt to Assets | 0.45 | 0.25 | Expensive |
Market Cap | 1.76M | 3.66B | Emerging |